Mypaid Sr (Dihydrocodeine Tartrate)

Dihydrocodeine Tartrate, the active ingredient in Mypaid Sr, is an opioid analgesic presented as an oral tablet for oral use. It provides pain relief for moderate intensity pain and suppresses cough in patients who need symptomatic control. GNH USA supplies Mypaid Sr as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dihydrocodeine Tartrate is an opioid analgesic that acts on the central nervous system to relieve pain and reduce cough reflex. - Moderate pain: provides analgesia for acute or chronic moderate‑intensity pain. - Cough: suppresses non‑productive cough by acting on the cough centre in the brain. - Post‑operative pain: helps manage pain after surgical procedures when stronger opioids are not required.

Dihydrocodeine Tartrate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: feeling of sickness or urge to vomit. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or reduced alertness. - Dizziness: sensation of light‑headedness or unsteadiness. - Dry mouth: reduced salivation leading to a parched feeling. - Vomiting: expulsion of stomach contents.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing faintness. - Dependence or addiction: compulsive use despite harmful consequences. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Seizures: rare occurrence of convulsive episodes. - Hepatotoxicity: potential liver injury with prolonged high‑dose use.

Before prescribing Dihydrocodeine Tartrate, clinicians should consider several safety measures. - Respiratory assessment: evaluate breathing function, especially in patients with COPD or sleep apnea. - Hepatic function: use caution in patients with liver impairment and adjust dose if needed. - Allergic history: avoid in individuals with known hypersensitivity to dihydrocodeine or other opioids. - Dependence monitoring: watch for signs of misuse, tolerance, or addiction during therapy. - Concomitant CNS depressants: limit use with alcohol, benzodiazepines, or other sedatives. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Dihydrocodeine Tartrate can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Other opioids: additive respiratory depression and sedation. - Benzodiazepines or barbiturates: heightened CNS depression and risk of overdose. - MAO inhibitors: can precipitate severe hypertension or serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole): increase dihydrocodeine plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may reduce conversion to active metabolites, altering analgesic effect. - Antihistamines: may enhance drowsiness. - Antidepressants (SSRIs, SNRIs): potential for serotonin syndrome when combined with MAO inhibitors. - Diuretics: may increase risk of hypotension.